|
Initial Encounter
Maribel Gonzalez, MS, ARNP, FNP-C
This session will provide a review of the components of initial patient encounter with the healthcare provider which can be one of the most important health visits for the patient. There are a variety of issues that need to be addressed at this visit including education of the patient regarding HIV, general health maintenance, and support services available. Additionally, a full history and physical are completed and baseline laboratory data are obtained. The data obtained at the initial visit will provide valuable information to direct the future care of the patient.
(Handouts)
Prevention of OIs and Immunizations in HIV Infected Adults
Don Kurtyka, ARNP, Ph.D
Prevention is an integral component of HIV care in the era of highly active antiretroviral therapy. This session will review the indications for initiating prophylaxis of opportunistic infections associated with HIV disease including appropriate agents and clinical indications. Additionally, vaccines used in caring for HIV-infected patients will be discussed including clinical indications, administration, and efficacy.
(Handouts)
|
Management of the ARV-Naïve Patient
Jennifer Janelle, MD, AAHIVM
There are several factors that need to be considered when designing an initial regimen for an antiretroviral-naïve patient. This session will provide a patient case-based overview of the initial regimen selection including: timing of initiation of therapy, preferred and alternative regimens according to the most recent DHHS guidelines, consideration of co-morbid conditions and other patient factors, and indications for changing therapy.
(Handouts)
HIV and TB
Michael Lauzardo, MD
Tuberculosis remains a leading cause of death among HIV-infected patients worldwide. Annual screening for latent tuberculosis infection remains an important recommended prevention strategy in HIV-infected individuals. Diagnosing and treating active tuberculosis in HIV-infected individuals can be challenging due to the often atypical presentation and drug-drug interactions among anti-TB and HIV therapies. This session will utilize cases to review screening and treatment of latent tuberculosis infection, clinical presentation of active tuberculosis disease, and treatment of active tuberculosis.
(Handouts)
|
Complications of ARV Therapy
Jose Montero, MD
As people infected with HIV are living longer as a result of receiving antiretroviral therapy, certain complications related to antiretroviral therapy have been recognized. This session will describe the common adverse effects associated with antiretroviral use and discuss strategies to minimize their risk and manage their consequences.
(Handouts)
Drug Interactions
Joanne Orrick, PharmD, AAHIVE
Due to continued advances in antiretroviral therapy, HIV-infected patients have an increased life-span. Patients are on multiple medications both for treatment and prevention of opportunistic diseases and treatment of co-morbid conditions. Identifying and managing drug-drug interactions can be challenging. This session will provide a case-based review of the most common and severe potential drug-drug interactions encountered in patients receiving antiretroviral therapy.
(Handouts)
Updated Pediatric Guidelines
Mobeen Rathore, MD
This session will outline the goals of antiretroviral treatment in HIV-infected children and adolescents. Topics include immunologic HIV RNA and laboratory monitoring, when to initiate antiretroviral therapy by age group, choices of combination therapy for antiretroviral-naïve children and adolescents, and laboratory monitoring of children on antiretroviral therapy. Experts will discuss choice of next antiretroviral regimen for treatment failure with evidence of drug resistance, the use of antiretroviral agents not approved for use in children for salvage therapy, and the management of medication toxicity and/or intolerance.
(Handouts) |
